Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata
CTP-543 Achieved its Primary Endpoint in the 8 mg Twice-Daily Cohort Company to Host Investor Conference Call Today at 8:30 a.m. ET LEXINGTON, Mass. --(BUSINESS WIRE)--Nov. 12, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced interim topline results from the first two cohorts of
View HTML
Toggle Summary Concert Pharmaceuticals to Participate at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)--Nov. 7, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences: The Stifel 2018 Healthcare Conference on November 14, 2018 , at 2:00 p.m.
View HTML
Toggle Summary Concert Pharmaceuticals Presents Preclinical Data on CTP-692, a Novel Drug Candidate for Schizophrenia, Supporting Potential to Improve Safety Profile of D-Serine
Findings Presented at American College of Toxicology 2018 Annual Meeting LEXINGTON, Mass. --(BUSINESS WIRE)--Nov. 5, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented preclinical results that support the potential of CTP-692, the Company’s novel drug candidate for schizophrenia,
View HTML
Toggle Summary Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Company Update
Conference Call Scheduled Today at 8:30 a.m. ET LEXINGTON, Mass. --(BUSINESS WIRE)--Nov. 1, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2018. “This is an exciting time at Concert as we advance multiple pipeline candidates, with our
View HTML
Toggle Summary Concert Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 1, 2018
LEXINGTON, Mass. --(BUSINESS WIRE)--Oct. 25, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2018 financial results on Thursday, November 1, 2018 , before the U.S. financial markets open. The Company will host a conference call and webcast
View HTML
Toggle Summary Concert Pharmaceuticals Amends Protocol of Phase 2a Trial to Evaluate 12 mg Twice-Daily Dose Cohort of CTP-543 for the Treatment of Alopecia Areata
Company On Track to Report Topline Data from the 4 mg and 8 mg Twice-Daily Cohorts in Fourth Quarter of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)--Sep. 26, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will include an additional cohort of patients in the Phase 2a trial
View HTML
Toggle Summary Concert Pharmaceuticals to Present at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)--Aug. 29, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Wells Fargo Securities 2018 Healthcare Conference on September 5, 2018 at 10:15 a.m.
View HTML
Toggle Summary Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Company Update
-- Clinical Programs Advance with CTP-543 Phase 2a Topline Data in Alopecia Areata and CTP-692 Phase 1 Trial Initiation Expected in the Fourth Quarter of 2018 -- -- Conference Call Scheduled Today at 8:30 A.M. EDT -- LEXINGTON, Mass. --(BUSINESS WIRE)--Aug. 2, 2018-- Concert Pharmaceuticals, Inc.
View HTML
Toggle Summary Concert Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018
LEXINGTON, Mass. --(BUSINESS WIRE)--Jul. 26, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2018 financial results on Thursday, August 2, 2018 , before the U.S. financial markets open. The Company will host a conference call and webcast at
View HTML
Toggle Summary Concert Pharmaceuticals Reports First Quarter 2018 Financial Results
Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass. --(BUSINESS WIRE)--May 3, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2018. “Concert has begun 2018 with strong momentum as our pipeline of first-in-class drug
View HTML